Review

hy n0139 (MedChemExpress)

Name: hy n0139
Brand: MedChemExpress
Rating: 94 (7 reviews)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress hy n0139
Hy N0139, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy n0139/product/MedChemExpress
Average 94 stars, based on 7 article reviews

hy n0139 - by Bioz Stars, 2026-02

94/100 stars

Images

Image Search Results

A schematic diagram illustrating the mechanism of troxerutin in improving diabetic cognitive dysfunction through inhibiting transient receptor potential melastatin 7-mediated mitochondrial fission. HG: High-concentration glucose; ATP: Adenosine triphosphate; TRPM7: Transient receptor potential melastatin 7; CaN: Calcineurin.

Journal: World Journal of Diabetes

Article Title: Troxerutin improves diabetic cognitive dysfunction by inhibiting mitochondrial fission mediated by transient receptor potential melastatin 7/calcineurin/dynamin-related protein 1 ser637

doi: 10.4239/wjd.v16.i8.106833

Figure Lengend Snippet: A schematic diagram illustrating the mechanism of troxerutin in improving diabetic cognitive dysfunction through inhibiting transient receptor potential melastatin 7-mediated mitochondrial fission. HG: High-concentration glucose; ATP: Adenosine triphosphate; TRPM7: Transient receptor potential melastatin 7; CaN: Calcineurin.

Article Snippet: The dm-T, db-T, and db-T-B groups were given intraperitoneal injections of troxerutin dissolved in physiological saline (60 mg/kg/day, MedChemExpress, China) for 8 weeks.

Techniques: Concentration Assay

The db/db mice exhibit cognitive dysfunction at 17 weeks of age. A: The body weight ( n = 8 mice per group); B: The fasting glucose level ( n = 8 mice per group); the animals’ cognitive functions were assessed by the Morris water-maze test, novel object recognition and Nesting test as described in “materials and methods” ( n = 8 mice per group); C: Escape latency (s); D: The times of crossing platform within 60 seconds in spatial probe test; E: Relative identification index; F: The scores of nesting; G: Swimming trajectories of the mice in exploration experiment. a P < 0.05, compared with dm group; b P < 0.05, compared with db group; c P < 0.05, compared with the db-T group. Data presented as mean ± SEM. dm: Control group; dm-T: Control + troxerutin group; db: Diabetes group; db-T: Diabetes + troxerutin group; db-T-B: Diabetes + troxerutin + bradykinin group.

Journal: World Journal of Diabetes

doi: 10.4239/wjd.v16.i8.106833

Figure Lengend Snippet: The db/db mice exhibit cognitive dysfunction at 17 weeks of age. A: The body weight ( n = 8 mice per group); B: The fasting glucose level ( n = 8 mice per group); the animals’ cognitive functions were assessed by the Morris water-maze test, novel object recognition and Nesting test as described in “materials and methods” ( n = 8 mice per group); C: Escape latency (s); D: The times of crossing platform within 60 seconds in spatial probe test; E: Relative identification index; F: The scores of nesting; G: Swimming trajectories of the mice in exploration experiment. a P < 0.05, compared with dm group; b P < 0.05, compared with db group; c P < 0.05, compared with the db-T group. Data presented as mean ± SEM. dm: Control group; dm-T: Control + troxerutin group; db: Diabetes group; db-T: Diabetes + troxerutin group; db-T-B: Diabetes + troxerutin + bradykinin group.

Article Snippet: The dm-T, db-T, and db-T-B groups were given intraperitoneal injections of troxerutin dissolved in physiological saline (60 mg/kg/day, MedChemExpress, China) for 8 weeks.

Techniques: Control

Troxerutin improved mitochondrial fission and cell apoptosis in the hippocampal tissue of diabetic cognitive dysfunction mice. A: Transmission electron microscopy images show a decrease in mitochondrial fission in the hippocampal tissue of db-T group compared to db group; B: The length and width of mitochondria were measured ( n = 20); C: Hematoxylin and eosin staining shows that hippocampal pyramidal cells injury was improved in db-T group compared to db group (400 ×); D: Relative of adenosine triphosphate level; E: The normalized mRNA expression of caspase-3, B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax), and Bcl-2; F: The relative protein expression of The relative protein expression of caspase-3, Bcl-2-associated X protein, and Bcl-2. Bradykinin is a transient receptor potential melastatin 7 agonist, and its addition diminished the neuroprotective effect of troxerutin. a P < 0.05, compared with dm group; b P < 0.05, compared with diabetes group; c P < 0.05, compared with diabetes + troxerutin group. Data presented as mean ± SEM. dm: Control group; dm-T: Control + troxerutin group; db: Diabetes group; db-T: Diabetes + troxerutin group; db-T-B: Diabetes + troxerutin + bradykinin group; Bax: B-cell lymphoma 2-associated X protein; Bcl-2: B-cell lymphoma 2.

Journal: World Journal of Diabetes

doi: 10.4239/wjd.v16.i8.106833

Figure Lengend Snippet: Troxerutin improved mitochondrial fission and cell apoptosis in the hippocampal tissue of diabetic cognitive dysfunction mice. A: Transmission electron microscopy images show a decrease in mitochondrial fission in the hippocampal tissue of db-T group compared to db group; B: The length and width of mitochondria were measured ( n = 20); C: Hematoxylin and eosin staining shows that hippocampal pyramidal cells injury was improved in db-T group compared to db group (400 ×); D: Relative of adenosine triphosphate level; E: The normalized mRNA expression of caspase-3, B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax), and Bcl-2; F: The relative protein expression of The relative protein expression of caspase-3, Bcl-2-associated X protein, and Bcl-2. Bradykinin is a transient receptor potential melastatin 7 agonist, and its addition diminished the neuroprotective effect of troxerutin. a P < 0.05, compared with dm group; b P < 0.05, compared with diabetes group; c P < 0.05, compared with diabetes + troxerutin group. Data presented as mean ± SEM. dm: Control group; dm-T: Control + troxerutin group; db: Diabetes group; db-T: Diabetes + troxerutin group; db-T-B: Diabetes + troxerutin + bradykinin group; Bax: B-cell lymphoma 2-associated X protein; Bcl-2: B-cell lymphoma 2.

Article Snippet: The dm-T, db-T, and db-T-B groups were given intraperitoneal injections of troxerutin dissolved in physiological saline (60 mg/kg/day, MedChemExpress, China) for 8 weeks.

Techniques: Transmission Assay, Electron Microscopy, Staining, Expressing, Control

Troxerutin improves mitochondrial energy metabolism abnormality and cell apoptosis induced by high-concentration glucose in hippocampal neuronal cells. A: Relative of adenosine triphosphate level; B: The normalized mRNA expression of caspase-3, B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax), and Bcl-2; C: The red fluorescence increased in the diabetes + troxerutin group, indicating an increase in mitochondrial membrane potential and a decrease in apoptotic cells; D: The relative protein expression of caspase-3, Bcl-2-associated X protein, and Bcl-2. Consistent with the animal results, the aforementioned effect of troxerutin was attenuated after overexpressing transient receptor potential melastatin 7. a P < 0.05, compared with normal control group; b P < 0.05, compared with high-concentration glucose group; c P < 0.05, compared with high-concentration glucose + troxerutin group. Data presented as mean ± SEM. TRPM7: Transient receptor potential melastatin 7; ATP: Adenosine triphosphate; NC: Normal control; HG: Hypertonic group; T: Troxerutin; Bax: B-cell lymphoma 2-associated X protein; Bcl-2: B-cell lymphoma 2.

Journal: World Journal of Diabetes

doi: 10.4239/wjd.v16.i8.106833

Figure Lengend Snippet: Troxerutin improves mitochondrial energy metabolism abnormality and cell apoptosis induced by high-concentration glucose in hippocampal neuronal cells. A: Relative of adenosine triphosphate level; B: The normalized mRNA expression of caspase-3, B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax), and Bcl-2; C: The red fluorescence increased in the diabetes + troxerutin group, indicating an increase in mitochondrial membrane potential and a decrease in apoptotic cells; D: The relative protein expression of caspase-3, Bcl-2-associated X protein, and Bcl-2. Consistent with the animal results, the aforementioned effect of troxerutin was attenuated after overexpressing transient receptor potential melastatin 7. a P < 0.05, compared with normal control group; b P < 0.05, compared with high-concentration glucose group; c P < 0.05, compared with high-concentration glucose + troxerutin group. Data presented as mean ± SEM. TRPM7: Transient receptor potential melastatin 7; ATP: Adenosine triphosphate; NC: Normal control; HG: Hypertonic group; T: Troxerutin; Bax: B-cell lymphoma 2-associated X protein; Bcl-2: B-cell lymphoma 2.

Article Snippet: The dm-T, db-T, and db-T-B groups were given intraperitoneal injections of troxerutin dissolved in physiological saline (60 mg/kg/day, MedChemExpress, China) for 8 weeks.

Techniques: Concentration Assay, Expressing, Fluorescence, Membrane, Control

Troxrutin improved the expression of transient receptor potential melastatin 7/calcineurin/p-dynamin-related protein 1 ser637 in high-concentration glucose-induced hippocampal neuronal cells. A: The normalized mRNA expression of transient receptor potential melastatin 7 (TRPM7) and calcineurin (CaN); B: Protein bands of TRPM7, CaN, and p-Drp1 ser637 ; C: The relative protein expression of TRPM7, CaN, and p-Drp1 ser637 . After overexpression of TRPM7, the above effects of troxrutin were weakened. a P < 0.05, compared with normal control group; b P < 0.05, compared with high-concentration glucose group; c P < 0.05, compared with high-concentration glucose + troxerutin group. Data presented as mean ± SEM. TRPM7: Transient receptor potential melastatin 7; Drp1: Dynamin-related protein 1; CaN: Calcineurin; NC: Normal control; HG: Hypertonic group; T: Troxerutin.

Journal: World Journal of Diabetes

doi: 10.4239/wjd.v16.i8.106833

Figure Lengend Snippet: Troxrutin improved the expression of transient receptor potential melastatin 7/calcineurin/p-dynamin-related protein 1 ser637 in high-concentration glucose-induced hippocampal neuronal cells. A: The normalized mRNA expression of transient receptor potential melastatin 7 (TRPM7) and calcineurin (CaN); B: Protein bands of TRPM7, CaN, and p-Drp1 ser637 ; C: The relative protein expression of TRPM7, CaN, and p-Drp1 ser637 . After overexpression of TRPM7, the above effects of troxrutin were weakened. a P < 0.05, compared with normal control group; b P < 0.05, compared with high-concentration glucose group; c P < 0.05, compared with high-concentration glucose + troxerutin group. Data presented as mean ± SEM. TRPM7: Transient receptor potential melastatin 7; Drp1: Dynamin-related protein 1; CaN: Calcineurin; NC: Normal control; HG: Hypertonic group; T: Troxerutin.

Article Snippet: The dm-T, db-T, and db-T-B groups were given intraperitoneal injections of troxerutin dissolved in physiological saline (60 mg/kg/day, MedChemExpress, China) for 8 weeks.

Techniques: Expressing, Concentration Assay, Over Expression, Control

Troxrutin improved diabetic cognitive dysfunction by inhibiting the transient receptor potential melastatin 7/calcineurin/p-dynamin-related protein 1 ser637 pathway. A: The normalized mRNA expression of transient receptor potential melastatin 7 (TRPM7) and calcineurin (CaN); B: The relative protein expression of TRPM7, CaN, and p-Drp1 ser637 ; C: Immunofluorescent staining of TRPM7, CaN, and p-Drp1 ser637 . a P < 0.05, compared with control group; b P < 0.05, compared with diabetes group; c P < 0.05, compared with diabetes + troxerutin group. Data presented as mean ± SEM. TRPM7: Transient receptor potential melastatin 7; Drp1: Dynamin-related protein 1; CaN: Calcineurin; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; DAPI: 4’,6-diamidino-2-phenylindole; dm: Control group; dm-T: Control + troxerutin group; db: Diabetes group; db-T: Diabetes + troxerutin group; db-T-B: Diabetes + troxerutin + bradykinin group.

Journal: World Journal of Diabetes

doi: 10.4239/wjd.v16.i8.106833

Figure Lengend Snippet: Troxrutin improved diabetic cognitive dysfunction by inhibiting the transient receptor potential melastatin 7/calcineurin/p-dynamin-related protein 1 ser637 pathway. A: The normalized mRNA expression of transient receptor potential melastatin 7 (TRPM7) and calcineurin (CaN); B: The relative protein expression of TRPM7, CaN, and p-Drp1 ser637 ; C: Immunofluorescent staining of TRPM7, CaN, and p-Drp1 ser637 . a P < 0.05, compared with control group; b P < 0.05, compared with diabetes group; c P < 0.05, compared with diabetes + troxerutin group. Data presented as mean ± SEM. TRPM7: Transient receptor potential melastatin 7; Drp1: Dynamin-related protein 1; CaN: Calcineurin; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; DAPI: 4’,6-diamidino-2-phenylindole; dm: Control group; dm-T: Control + troxerutin group; db: Diabetes group; db-T: Diabetes + troxerutin group; db-T-B: Diabetes + troxerutin + bradykinin group.

Article Snippet: The dm-T, db-T, and db-T-B groups were given intraperitoneal injections of troxerutin dissolved in physiological saline (60 mg/kg/day, MedChemExpress, China) for 8 weeks.

Techniques: Expressing, Staining, Control

Absorption spectrum of 20 μM troxerutin in water. The molecular structure of troxerutin is shown in the inset. The path length is 1 cm.

Journal: ACS Physical Chemistry Au

Article Title: Evaluating the Fluorescence Quenching of Troxerutin for Commercial UV Sunscreen Filters

doi: 10.1021/acsphyschemau.4c00070

Figure Lengend Snippet: Absorption spectrum of 20 μM troxerutin in water. The molecular structure of troxerutin is shown in the inset. The path length is 1 cm.

Article Snippet: Symrise has patented the use of troxerutin for the quenching of DPDT emission; in this study, the quenching effects of troxerutin are investigated for both PBSA and DPDT.

Techniques:

TEA spectra presented as false color heatmaps for (a) PBSA and (b) DPDT on human skin mimic with troxerutin, following excitation at their respective λ max . There is a 1:1 ratio of PBSA to troxerutin and a 1:3 ratio of DPDT to troxerutin. In both cases, the time delay is linear up to 1 ps and logarithmic from 1 to 1800 ps. The EADS obtained from the global sequential fitting model in the Glotaran software package are shown in parts (c, d) for PBSA and DPDT, respectively. The corresponding lifetimes for EADS are presented for each graph.

Journal: ACS Physical Chemistry Au

Article Title: Evaluating the Fluorescence Quenching of Troxerutin for Commercial UV Sunscreen Filters

doi: 10.1021/acsphyschemau.4c00070

Figure Lengend Snippet: TEA spectra presented as false color heatmaps for (a) PBSA and (b) DPDT on human skin mimic with troxerutin, following excitation at their respective λ max . There is a 1:1 ratio of PBSA to troxerutin and a 1:3 ratio of DPDT to troxerutin. In both cases, the time delay is linear up to 1 ps and logarithmic from 1 to 1800 ps. The EADS obtained from the global sequential fitting model in the Glotaran software package are shown in parts (c, d) for PBSA and DPDT, respectively. The corresponding lifetimes for EADS are presented for each graph.

Article Snippet: Symrise has patented the use of troxerutin for the quenching of DPDT emission; in this study, the quenching effects of troxerutin are investigated for both PBSA and DPDT.

Techniques: Software

Tabulated Lifetimes of DPDT and PBSA in Water at 500 μM and on Skin in the Absence and Presence of Troxerutin

Journal: ACS Physical Chemistry Au

Article Title: Evaluating the Fluorescence Quenching of Troxerutin for Commercial UV Sunscreen Filters

doi: 10.1021/acsphyschemau.4c00070

Figure Lengend Snippet: Tabulated Lifetimes of DPDT and PBSA in Water at 500 μM and on Skin in the Absence and Presence of Troxerutin

Article Snippet: Symrise has patented the use of troxerutin for the quenching of DPDT emission; in this study, the quenching effects of troxerutin are investigated for both PBSA and DPDT.

Techniques:

Review

Structured Review

Images

Similar Products

Image Search Results